Loading company…
PrognomiQ develops multi-omics tests for early disease detection, including for complex diseases such as cancer.
PrognomiQ develops diagnostic tests that combine proteomic, genomic, and metabolomic data to support early disease detection. The company is based in San Mateo, US, and is at Series D stage. In August 2024, it raised USD 34.32 mn in a Series D round led by Seer, Inc., with Bruker Corporation and aMoon participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in